Tirdzniecība Caribou Biosciences, Inc. - CRBU CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.06 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.024068% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.001846% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 5.02 |
| Atvērt* | 4.89 |
| Izmaiņas par 1 gadu* | -44.56% |
| Dienas Diapazons* | 4.82 - 4.97 |
| 52 ned Diapazons | 4.83-13.19 |
| Vidējais apjoms (10 dienas) | 595.92K |
| Vidējais apjoms (3 mēneši) | 10.45M |
| Tirgus Kapitalizācija | 304.05M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 61.30M |
| Ieņēmumi | 13.85M |
| EPS | -1.63 |
| Dividende (Ienesīgums %) | N/A |
| Beta | -100.00K |
| Nākamās Peļņas Datums | N/A |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Mar 17, 2023 | 4.91 | -0.02 | -0.41% | 4.93 | 5.02 | 4.80 |
| Mar 16, 2023 | 5.02 | -0.07 | -1.38% | 5.09 | 5.15 | 4.91 |
| Mar 15, 2023 | 5.15 | 0.10 | 1.98% | 5.05 | 5.25 | 5.02 |
| Mar 14, 2023 | 5.18 | -0.25 | -4.60% | 5.43 | 5.51 | 5.10 |
| Mar 13, 2023 | 5.30 | 0.25 | 4.95% | 5.05 | 5.34 | 5.02 |
| Mar 10, 2023 | 5.14 | -0.29 | -5.34% | 5.43 | 5.48 | 4.93 |
| Mar 9, 2023 | 5.48 | -0.35 | -6.00% | 5.83 | 5.85 | 5.33 |
| Mar 8, 2023 | 5.85 | 0.02 | 0.34% | 5.83 | 5.92 | 5.75 |
| Mar 7, 2023 | 5.86 | 0.03 | 0.51% | 5.83 | 6.04 | 5.70 |
| Mar 6, 2023 | 5.77 | -0.32 | -5.25% | 6.09 | 6.09 | 5.54 |
| Mar 3, 2023 | 6.09 | 0.17 | 2.87% | 5.92 | 6.11 | 5.86 |
| Mar 2, 2023 | 5.89 | 0.01 | 0.17% | 5.88 | 5.98 | 5.82 |
| Mar 1, 2023 | 6.00 | 0.03 | 0.50% | 5.97 | 6.13 | 5.88 |
| Feb 28, 2023 | 6.06 | 0.17 | 2.89% | 5.89 | 6.17 | 5.88 |
| Feb 27, 2023 | 5.97 | 0.16 | 2.75% | 5.81 | 6.09 | 5.78 |
| Feb 24, 2023 | 5.76 | -0.14 | -2.37% | 5.90 | 5.94 | 5.70 |
| Feb 23, 2023 | 6.07 | -0.12 | -1.94% | 6.19 | 6.23 | 5.93 |
| Feb 22, 2023 | 6.17 | 0.07 | 1.15% | 6.10 | 6.24 | 5.98 |
| Feb 21, 2023 | 6.09 | -0.39 | -6.02% | 6.48 | 6.73 | 6.08 |
| Feb 17, 2023 | 6.82 | 0.33 | 5.08% | 6.49 | 6.83 | 6.36 |
Caribou Biosciences, Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Kopējie ienākumi | 5.788 | 12.361 | 9.598 |
| Ienākumi | 5.788 | 12.361 | 9.598 |
| Kopējie Darbības Izdevumi | 40.093 | 48.485 | 74.993 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 16.458 | 14.06 | 24.322 |
| Pētniecība un Attīstība | 23.635 | 34.425 | 52.255 |
| Darbības Izdevumi | -34.305 | -36.124 | -65.395 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 3.337 | -0.517 | 0.14 |
| Citi, Neto | 0 | 0.514 | -1.347 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -30.968 | -36.127 | -66.602 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -23.431 | -34.308 | -66.923 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -23.431 | -34.308 | -66.923 |
| Neto Ienākumi | -23.431 | -34.308 | -66.923 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -23.431 | -34.308 | -66.923 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -23.431 | -34.308 | -66.923 |
| Atšķaidītie Neto Ienākumi | -23.431 | -34.308 | -66.923 |
| Atšķaidītie Ienākumi par Akcijām | 56.7092 | 56.7092 | 31.6632 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.41318 | -0.60498 | -2.11359 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.41318 | -0.60498 | -2.1461 |
| Neparedzēti Izdevumi (Ienākumi) | -1.584 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 1.586 | 1.476 | 3.977 | 2.559 | 2.664 |
| Ienākumi | 1.586 | 1.476 | 3.977 | 2.559 | 2.664 |
| Kopējie Darbības Izdevumi | 14.761 | 15.856 | 22.593 | 22.964 | 23.517 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 4.596 | 5.113 | 6.76 | 7.853 | 9.593 |
| Pētniecība un Attīstība | 10.165 | 12.327 | 15.833 | 15.111 | 13.924 |
| Darbības Izdevumi | -13.175 | -14.38 | -18.616 | -20.405 | -20.853 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -0.001 | 0.044 | 0.022 | 0.076 | 0.163 |
| Citi, Neto | 0.017 | 0.025 | -2.38 | 2.171 | 1.602 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -13.159 | -14.311 | -20.974 | -18.158 | -19.088 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Neto Ienākumi | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Atšķaidītie Neto Ienākumi | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Atšķaidītie Ienākumi par Akcijām | 56.7092 | 10.2618 | 45.8896 | 60.4941 | 60.5462 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.23204 | -1.39459 | -0.45705 | -0.30547 | -0.31526 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.23204 | -1.54895 | -0.45705 | -0.30547 | -0.31526 |
| Neparedzēti Izdevumi (Ienākumi) | -1.584 | 0 | 0 |
- Ikgadējs
- Ceturkšņa
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 57.008 | 24.306 | 391.192 |
| Nauda un Īstermiņa Ieguldījumi | 49.471 | 15.953 | 375.832 |
| Nauda un Ekvivalenti | 41.07 | 15.953 | 240.42 |
| Īstermiņa Ieguldījumi | 8.401 | 0 | 135.412 |
| Debitoru Parādu Kopsumma, Neto | 3.982 | 5.16 | 8.124 |
| Accounts Receivable - Trade, Net | 0.841 | 1.478 | 2.641 |
| Prepaid Expenses | 3.182 | 2.433 | 6.565 |
| Other Current Assets, Total | 0.373 | 0.76 | 0.671 |
| Total Assets | 61.933 | 36.046 | 442.356 |
| Property/Plant/Equipment, Total - Net | 4.332 | 3.502 | 4.887 |
| Property/Plant/Equipment, Total - Gross | 6.59 | 6.598 | 8.964 |
| Accumulated Depreciation, Total | -2.258 | -3.096 | -4.077 |
| Long Term Investments | 0 | 7.626 | 45.302 |
| Other Long Term Assets, Total | 0.593 | 0.612 | 0.975 |
| Total Current Liabilities | 10.078 | 12.389 | 25.829 |
| Accounts Payable | 2.537 | 2.601 | 3.99 |
| Accrued Expenses | 5.653 | 8.151 | 12.089 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.654 | 0 |
| Other Current Liabilities, Total | 1.888 | 0.983 | 9.75 |
| Total Liabilities | 13.147 | 18.16 | 54.531 |
| Total Long Term Debt | 0 | 0.924 | 0 |
| Long Term Debt | 0 | 0.924 | 0 |
| Deferred Income Tax | 0.65 | 0.155 | 0.476 |
| Other Liabilities, Total | 2.419 | 4.692 | 28.226 |
| Total Equity | 48.786 | 17.886 | 387.825 |
| Preferred Stock - Non Redeemable, Net | 41.323 | 41.323 | 0 |
| Common Stock | 0.001 | 0.001 | 0.006 |
| Additional Paid-In Capital | 4.025 | 7.433 | 485.748 |
| Retained Earnings (Accumulated Deficit) | 3.437 | -30.871 | -97.794 |
| Total Liabilities & Shareholders’ Equity | 61.933 | 36.046 | 442.356 |
| Total Common Shares Outstanding | 56.7092 | 56.7092 | 60.2632 |
| Other Equity, Total | -0.135 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 155.925 | 142.967 | 449.047 | 391.192 | 368.01 |
| Nauda un Īstermiņa Ieguldījumi | 145.924 | 129.524 | 435.31 | 375.832 | 353.731 |
| Nauda un Ekvivalenti | 145.924 | 129.524 | 435.31 | 240.42 | 147.63 |
| Debitoru Parādu Kopsumma, Neto | 5.825 | 8.407 | 7.785 | 8.124 | 6.037 |
| Accounts Receivable - Trade, Net | 1.049 | 0.832 | 2.431 | 2.641 | 1.868 |
| Prepaid Expenses | 3.096 | 3.759 | 5.189 | 6.565 | 7.276 |
| Other Current Assets, Total | 1.08 | 1.277 | 0.763 | 0.671 | 0.966 |
| Total Assets | 167.965 | 158.397 | 461.96 | 442.356 | 445.997 |
| Property/Plant/Equipment, Total - Net | 3.38 | 4.408 | 4.477 | 4.887 | 31.765 |
| Property/Plant/Equipment, Total - Gross | 6.695 | 7.952 | 8.282 | 8.964 | 36.15 |
| Accumulated Depreciation, Total | -3.315 | -3.544 | -3.805 | -4.077 | -4.385 |
| Long Term Investments | 7.626 | 7.626 | 7.626 | 45.302 | 44.758 |
| Other Long Term Assets, Total | 1.034 | 3.396 | 0.81 | 0.975 | 1.464 |
| Total Current Liabilities | 22.21 | 26.007 | 26.158 | 25.829 | 26.667 |
| Accounts Payable | 3.117 | 4.029 | 3.482 | 3.99 | 1.814 |
| Accrued Expenses | 10.929 | 11.034 | 12.288 | 12.089 | 11.215 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.655 | 0 | 0 | 0 | |
| Other Current Liabilities, Total | 7.509 | 10.944 | 10.388 | 9.75 | 13.638 |
| Total Liabilities | 53.504 | 55.938 | 57.559 | 54.531 | 74.2 |
| Total Long Term Debt | 0.926 | 0 | 0 | 0 | 0 |
| Long Term Debt | 0.926 | 0 | 0 | 0 | |
| Deferred Income Tax | 0.155 | 0.155 | 0.155 | 0.476 | 0.476 |
| Other Liabilities, Total | 30.213 | 29.776 | 31.246 | 28.226 | 47.057 |
| Total Equity | 114.461 | 102.459 | 404.401 | 387.825 | 371.797 |
| Preferred Stock - Non Redeemable, Net | 150.15 | 150.15 | 0 | 0 | 0 |
| Common Stock | 0.001 | 0.001 | 0.006 | 0.006 | 0.006 |
| Additional Paid-In Capital | 8.34 | 10.649 | 483.71 | 485.748 | 489.762 |
| Retained Earnings (Accumulated Deficit) | -44.03 | -58.341 | -79.315 | -97.794 | -116.882 |
| Total Liabilities & Shareholders’ Equity | 167.965 | 158.397 | 461.96 | 442.356 | 445.997 |
| Total Common Shares Outstanding | 56.7092 | 59.9708 | 60.0213 | 60.2632 | 60.6896 |
| Īstermiņa Ieguldījumi | 135.412 | 206.101 | |||
| Other Equity, Total | -0.135 | -1.089 |
- Ikgadējs
- Ceturkšņa
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -23.431 | -34.308 | -66.923 |
| Nauda no Darbības | -32.006 | -33.215 | -32.519 |
| Nauda no Darbības | 0.751 | 0.9 | 0.984 |
| Bezskaidras Naudas Preces | -1.059 | 0.016 | 4.353 |
| Cash Taxes Paid | 1.809 | 0.021 | 0.011 |
| Izmaiņas Apgrozāmajā Kapitālā | -8.267 | 0.177 | 29.067 |
| Nauda no Ieguldījumu Darbībām | 27.233 | 6.363 | -176.397 |
| Kapitālie Izdevumi | -0.884 | -0.317 | -2.121 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 28.117 | 6.68 | -174.276 |
| Nauda no Darbībām ar Finansēšanu | 0.172 | 1.735 | 433.429 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 0.217 | 1.848 | 432.398 |
| Parādu Izsniegšana (Atkāpšanās), Neto | -0.045 | -0.113 | 1.031 |
| Neto Izmaiņas Naudā | -4.601 | -25.117 | 224.513 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -13.159 | -27.47 | -48.444 | -66.923 | -19.088 |
| Cash From Operating Activities | 20.313 | 3.837 | -11.13 | -32.519 | -21.673 |
| Cash From Operating Activities | 0.221 | 0.451 | 0.711 | 0.984 | 0.308 |
| Non-Cash Items | 1.036 | 1.542 | 4.88 | 4.353 | 2.215 |
| Cash Taxes Paid | 0 | 0.011 | 0.011 | 0.011 | 0 |
| Cash Interest Paid | 0.001 | 0 | |||
| Changes in Working Capital | 32.215 | 29.314 | 31.723 | 29.067 | -5.108 |
| Cash From Investing Activities | -0.022 | -0.506 | -2.436 | -176.397 | -72.107 |
| Capital Expenditures | -0.022 | -0.506 | -1.436 | -2.121 | -0.723 |
| Other Investing Cash Flow Items, Total | 0 | 0 | -1 | -174.276 | -71.384 |
| Cash From Financing Activities | 109.68 | 110.286 | 432.969 | 433.429 | 0.99 |
| Issuance (Retirement) of Stock, Net | 109.799 | 109.957 | 431.938 | 432.398 | 0.99 |
| Issuance (Retirement) of Debt, Net | -0.119 | 1.031 | 1.031 | 1.031 | 0 |
| Net Change in Cash | 129.971 | 113.617 | 419.403 | 224.513 | -92.79 |
| Financing Cash Flow Items | -0.702 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| PFM Health Sciences, LP | Hedge Fund | 7.2754 | 4459783 | -1540217 | 2022-12-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.6832 | 4096777 | 277588 | 2022-12-31 | LOW |
| Haurwitz (Rachel E. Ph.D.) | Individual Investor | 5.4966 | 3369395 | 0 | 2022-08-01 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.2184 | 3198893 | 803423 | 2022-12-31 | LOW |
| Avidity Partners Management LP | Hedge Fund | 4.7025 | 2882600 | -290000 | 2022-12-31 | HIGH |
| Rokos Capital Management LLP | Hedge Fund | 4.4831 | 2748139 | 840630 | 2022-12-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.1939 | 2570827 | 26789 | 2022-12-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 4.1662 | 2553878 | -737020 | 2022-12-31 | LOW |
| Elmwood Wealth Management, INC. | Investment Advisor | 3.8569 | 2364240 | 0 | 2022-12-31 | LOW |
| EIDP Inc | Corporation | 3.3573 | 2058000 | -1093311 | 2022-05-31 | MED |
| BofA Global Research (US) | Research Firm | 3.008 | 1843902 | 1668395 | 2022-12-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 2.3541 | 1443046 | -547 | 2022-12-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 1.982 | 1214933 | 30615 | 2022-12-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6819 | 1030987 | 45617 | 2022-12-31 | LOW |
| Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 1.4575 | 893424 | -138016 | 2022-12-31 | LOW |
| Fidelity International | Investment Advisor | 1.404 | 860666 | 0 | 2022-12-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3944 | 854738 | 55247 | 2022-12-31 | HIGH |
| Maverick Capital, Ltd. | Hedge Fund | 1.0645 | 652542 | 0 | 2022-12-31 | MED |
| Tekla Capital Management LLC | Investment Advisor | 0.9252 | 567147 | 0 | 2022-12-31 | LOW |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.9215 | 564855 | -1059 | 2022-12-31 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group 500000+
Tirgotāji
92000+
Ikmēneša aktīvie klienti
$53000000+
Ikmēneša ieguldījumu apjoms
$30000000+
Izmēģināt tagad Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Caribou Biosciences, Inc. Company profile
Par Caribou Biosciences, Inc.
Caribou Biosciences, Inc. ir Amerikas Savienotajās Valstīs dibināts klīniskās stadijas biotehnoloģiju uzņēmums. Lai atklātu un izstrādātu uz imūnsistēmas šūnām balstītas vēža ārstēšanas metodes, uzņēmums izmanto genoma rediģēšanu ar regulāri izkliedētiem īsiem palindromiskiem atkārtojumiem (CRISPR). Uzņēmums koncentrējas uz genoma rediģētu gatavo CAR-T šūnu un dabisko killer (NK) šūnu terapiju izstrādi dažādiem audzēju tipiem. Uzņēmums piedāvā arī licences uz CRISPR-Cas9 intelektuālā īpašuma pamatiem vairākās jomās, tostarp pētniecības rīkiem, iekšējai pētniecības izmantošanai, diagnostikai un rūpnieciskajai biotehnoloģijai. Uzņēmuma izstrādes procesā ietilpst CB-010, CB-011, CB-012 un CB-020.
| Industry: | Biotechnology & Medical Research (NEC) |
2929 7Th Street, Ste 120
94710
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com